Navigation Links
Chantix associated with 72 percent increased risk of serious CV events
Date:7/4/2011

WINSTON-SALEM, N.C. July 4, 2011 Smoking cigarettes is a dangerous habit that many are struggling to break, but for the smokers who choose to use one of the most popular smoking cessation drugs on the market, new warnings about the risk of serious cardiovascular events are on their way.

A new study by researchers at Wake Forest Baptist Medical Center, in collaboration with researchers at Johns Hopkins University School of Medicine and the University of East Anglia, in the United Kingdom, shows that the use of varenicline marketed by Pfizer under the brand name ChantixTM is associated with a 72 percent increased risk of hospitalization due to a serious adverse cardiovascular (CV) event, such as heart attack or arrhythmia.

The study appears in the July 4 issue of CMAJ (the Canadian Medical Association Journal).

"We have known for many years that Chantix is one of the most harmful prescription drugs on the U.S. market, based on the number of serious adverse effects reported to the FDA (U.S. Food and Drug Administration)," said Curt D. Furberg, M.D., Ph.D., a professor of Public Health Sciences at Wake Forest Baptist, lead investigator on the study, and a nationally-recognized leader in drug safety research. "It causes loss of consciousness, visual disturbances, suicides, violence, depression and worsening of diabetes. To this list we now can add serious cardiovascular events."

Heart disease is a common cause of serious illness and death in smokers and is often a reason for people to stop smoking. Varenicline is one of the most commonly used drugs to help people quit smoking worldwide. When varenicline was launched in 2006, the FDA safety reviewers reported that existing data indicated it could raise the risk of adverse cardiac events. The FDA recently updated the label for Chantix based on a small increased risk of cardiovascular events among smokers with heart disease.

The team of researchers sought to investigate the serious cardiac effects of varenicline in tobacco users (smokers or smokeless tobacco users) compared with placebo in clinical trials. They looked at 14 double-blind, randomized, controlled trials that included more than 8,200 patients (4,908 people on varenicline and 3,308 taking placebos). All trials, except one, excluded people with a history of heart disease, and none of the studies followed participants for longer than one year.

In the study, 52 of 4,908 (1.06%) participants taking varenicline had adverse events compared with 27 of 3,308 (0.82%) participants on placebo, while the number of people who died in each group was the same (seven). The majority of study participants were men and averaged less than 45 years of age.

"Among tobacco users varenicline use was associated with a significantly increased risk of serious adverse cardiovascular events greater than 72 percent," the researchers wrote. "These increased risks of adverse cardiovascular events are seen in smokers with or without heart disease."

The researchers noted additional risks of using the drug, found in previous studies, that led to an existing box warning from the FDA risks of depression, agitation and suicidal thoughts.

"People should be concerned," said Sonal Singh, M.D., M.P.H., lead author on the study from Johns Hopkins University Medical Center. "They don't need Chantix to quit and this is another reason to consider avoiding Chantix altogether."

In the paper, the researchers wrote that "clinicians should carefully balance the risk of serious cardiovascular events and other serious neuropsychiatric adverse events associated with varenicline against their known benefits on smoking cessation."

"The sum of all serious adverse effects of Chantix clearly outweigh the most positive effect of the drug in my view," Furberg said. "The time has come for the FDA to withdraw the drug from the market."


'/>"/>

Contact: Jessica Guenzel
jguenzel@wakehealth.edu
336-716-3487
Wake Forest Baptist Medical Center
Source:Eurekalert

Related medicine news :

1. South Carolina Attorney Says Legal Options Still Available To Those Harmed By Chantix
2. Web- and phone-based counseling work well to quit smoking with Chantix
3. Smoking-Cessation Drug Chantix Linked to Heart Problems
4. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
5. Certain pain medications do not appear to be associated with skin cancer risk
6. News brief: ALDH associated with worse overall survival in patients with pancreatic adenocarcinoma
7. New research shows emotional impact of low sexual desire and associated distress
8. Increased HAART coverage associated with 50 percent drop
9. Pretreatment SUV associated with head and neck cancer treatment outcomes, may help decide treatment plans
10. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
11. MedQuist Launches EHR Integration for Dictations Associated with Template-based Clinical Documentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 19, 2017 , ... Aerolib Healthcare Solutions ... Clinical and Regulatory education for Physicians, Physician Advisors, Case managers, Utilization Review ... of Disease Specific Documentation Improvement. , The Aerolib Learning Management System is ...
(Date:1/19/2017)... ... 19, 2017 , ... With the cold weather here, many people will have to clear snow ... clearing large amounts of snow, but they can be dangerous when used incorrectly. That’s why ... Commission for the proper use of snow blowers:, , When removing ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media company ... Heart Association (AHA) to produce a three-part video series that uses humor to highlight ... of the launch of AHA’s Healthy For Good™ movement, which is designed to inspire ...
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is ... year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday ... clinic’s leading recovery program. , “We know it’s easy to get carried ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... recently provided a new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health ... facility were used to facilitate a recapitalization of MedPro led by Harren Equity ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis instruments and consumables for the medical ... to discuss its financial results for the third quarter ... will be at 4:15 p.m. ET on Thursday, January ... the third quarter fiscal year 2017 after the market ...
(Date:1/19/2017)... January 19, 2017 Shire plc ... the U.S. Food and Drug Administration (FDA) has acknowledged ... Drug Application (NDA) for SHP465, a long-acting, triple-bead, mixed ... potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA ... June 20, 2017, the designated Prescription Drug User Fee ...
(Date:1/19/2017)... 19, 2017 While various ... about reducing the FDA,s regulatory strictness as a ... medical drug industry, many of the leading biotech ... trials and development of advanced drug treatments and ... recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology: